Oppenheimer Upgrades Cubist Pharmaceuticals (CBST) to Perform
CBST Hot Sheet
Rating Summary:6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 5 | New: 9
Oppenheimer upgrades Cubist Pharmaceuticals (Nasdaq: CBST) from Underperform to Perform. Price target $17.
To see more analyst ratings on CBST Click Here.
Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.
To see more analyst ratings on CBST Click Here.
Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Sterne Agee Raising PT & Estimates on Hewlett-Packard (HPQ); Surprisingly Strong Quarter
- TD Securities Upgrades Rogers Communications (RCI) to Buy; Negatives Priced In
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
